INM
NASDAQInMed Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.32-0.25 (-15.92%)
2026-07-012026-10-02
News · 26 weeks33+67%
2026-04-122026-10-04
Mix1790d
- SEC Filings13(76%)
- Insider3(18%)
- Other1(6%)
Latest news
25 items- SECSEC Form EFFECT filed by InMed Pharmaceuticals Inc.EFFECT - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 424B3 filed by InMed Pharmaceuticals Inc.424B3 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECAmendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.S-4/A - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $118,076 worth of shares (91,101 units at $1.30) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECAmendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.S-4/A - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECSEC Form 10-K filed by InMed Pharmaceuticals Inc.10-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- PRMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelineWALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued development of Mentari's pipeline of targeted biologics aimed at improving outcomes for people living with migraines. Key transaction details for the private placement include:The additional $200 million private placement consisted of common stock and pre-funded warrants to purchase common stock (the "Private Place
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERLarge owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Vivo Opportunity, Llc bought $10,148 worth of shares (6,551 units at $1.55) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECSEC Form S-4 filed by InMed Pharmaceuticals Inc.S-4 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- INSIDERLarge owner Vivo Opportunity, Llc bought $391,555 worth of shares (249,227 units at $1.57) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERNew insider Vivo Opportunity, Llc claimed ownership of 541,752 shares (SEC Form 3)3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- PRInMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing RequirementsVancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Com
- INSIDERLarge owner Adar1 Capital Management, Llc bought $721,548 worth of shares (468,551 units at $1.54) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERNew insider Adar1 Capital Management, Llc claimed ownership of 331,449 shares (SEC Form 3)3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
INM FAQ
6 questionsWhat does InMed Pharmaceuticals Inc. do?
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the...Where does INM stock trade?
InMed Pharmaceuticals Inc. (INM) is listed on NASDAQ.What sector and industry is INM in?
InMed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INM?
InMed Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $600.00 price target on 2021-11-29. Recent price targets cluster around $600.00.What companies are similar to INM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INM side-by-side with any of them on Quantisnow.How can I track INM on Quantisnow?
Quantisnow aggregates InMed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INM to receive live email and push alerts on every new disclosure.